Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: An earlier analysis of this phase 3 trial showed that the addition of a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor to endocrine therapy provided a greater benefit with regard to progression-free survival than endocrine therapy alone in premenopausal or perimenopausal patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Here we report the results of a protocol-specified interim analysis of the key secondary end point of overall survival. METHODS: We randomly assigned patients to receive either ribociclib or placebo in addition to endocrine therapy (goserelin and either a nonsteroidal aromatase inhibitor or tamoxifen). Overall survival was evaluated with the use of a stratified log-rank test and summarized with the use of Kaplan-Meier methods. RESULTS: A total of 672 patients were included in the intention-to-treat population. There were 83 deaths among 335 patients (24.8%) in the ribociclib group and 109 deaths among 337 patients (32.3%) in the placebo group. The addition of ribociclib to endocrine therapy resulted in significantly longer overall survival than endocrine therapy alone. The estimated overall survival at 42 months was 70.2% (95% confidence interval [CI], 63.5 to 76.0) in the ribociclib group and 46.0% (95% CI, 32.0 to 58.9) in the placebo group (hazard ratio for death, 0.71; 95% CI, 0.54 to 0.95; P = 0.00973 by log-rank test). The survival benefit seen in the subgroup of 495 patients who received an aromatase inhibitor was consistent with that in the overall intention-to-treat population (hazard ratio for death, 0.70; 95% CI, 0.50 to 0.98). The percentage of patients who received subsequent antineoplastic therapy was balanced between the groups (68.9% in the ribociclib group and 73.2% in the placebo group). The time from randomization to disease progression during receipt of second-line therapy or to death was also longer in the ribociclib group than in the placebo group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.55 to 0.87). CONCLUSIONS: This trial showed significantly longer overall survival with a CDK4/6 inhibitor plus endocrine therapy than with endocrine therapy alone among patients with advanced hormone-receptor-positive, HER2-negative breast cancer. No new concerns regarding toxic effects emerged with longer follow-up. (Funded by Novartis; MONALEESA-7 ClinicalTrials.gov number, NCT02278120.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in view of the OS benefit seen in several trials,36, 37, 38, 39, 40, 41, 42 both in the first- and second-line settings”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“The last 2 years have seen the establishment of cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET) as the standard of care for ER-positive/HER2-negative ABC”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“substantial PFS benefit and good toxicity profile.36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“the combination of tamoxifen and ribociclib led to increased cardiotoxicity (arrhythmia)”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“These agents can be combined with an aromatase inhibitor (AI) or fulvestrant, and are effective in de novo or recurrent ABC, in first or second line, in cases of primary or secondary resistance, in postmenopausal and premenopausal women (the latter with ovarian function suppression/ablation), and in men (preferably with a luteinising hormone-releasing hormone agonist).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Self-citationFinn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Self-citationSledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680
Self-citationOverall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810527 · Cited by 1,276
Self-citation4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,171
Self-citationSlamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9909 · Cited by 1,121
Self-citation
Cited by
Items 301–400 of 1,000
Vila, M. M., Barco, S. D., Gil‐Gil, M., Ochoa, C., & Villanueva-Vázquez, R. (2020) · The Breast · doi:10.1016/j.breast.2020.06.007 · Cited by 26
“The data from the MONALEESA-7 trial have shown longer OS and improved QoL in premenopausal HRþ/HER2-negative MBC patients treated with ribociclib plus endocrine therapy [44,53,54].”
MethodA systematic review and meta-analysis of selected toxicity endpoints of alpelisib
Shields, M. D., Mo, Q., Armitage, M., Sharpe, S. C., & Costa, R. L. B. (2020) · Oncotarget · doi:10.18632/oncotarget.27770 · Cited by 21
“Interestingly, other PI3K inhibitors have been associated with a toxicity profile similar to that of alpelisib, including an increased risk of hyperglycemia [11, 12].”
BackgroundMuttiah, C., Whittle, J. R., Oakman, C. A., & Lindeman, G. J. (2022) · Future Oncology · doi:10.2217/fon-2021-1450 · Cited by 23
A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis
Krishnamurthy, J., Luo, J. R., Suresh, R., Ademuyiwa, F. O., Rigden, C. E., Rearden, T. P., Clifton, K., Weilbaecher, K. N., Frith, A. E., Roshal, A., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00399-w · Cited by 23
Tsao, A.-N., Chuang, Y.-S., Lin, Y.-C., Su, Y., & Chao, T. (2022) · Oncology Reports · doi:10.3892/or.2022.8316 · Cited by 21
Xu, H., Wang, Y., Han, Y., Wu, Y., Wang, J., & Xu, B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.956464 · Cited by 24
“04 II Everolimus + Leuprorelin + Letrozole (92) Leuprorelin + Letrozole (45) 0(49)/1 (34)/≥2(17) 0(58)/1(29)/ ≥2(13) 5.”
Douganiotis, G., Kesisis, G., Lalla, E., Korantzis, I., Boukovinas, I., & Papazisis, K. T. (2022) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10146 · Cited by 24
Anti-Hormonal Therapy in Breast Cancer and Its Effect on the Blood-Brain Barrier
Curtaz, C. J., Kiesel, L., Meybohm, P., Wöckel, A., & Burek, M. (2022) · Cancers · doi:10.3390/cancers14205132 · Cited by 27
“In its last statement from 2022, the AGO recommends therapy with GnRHa + Fulvestrant + CDK4/6i [35] with the highest recommendation grade or using GnRHa + AI + Ribociclib based on results of the MONALEESA-7 trial [35,44,45].”
MethodZhou, J., Wu, X., Zhang, H., Wang, X., Yuan, Y., Zhang, S., Jiang, Z., & Wang, T. (2022) · The Breast · doi:10.1016/j.breast.2022.10.018 · Cited by 23
What’s the Price? Toxicities of Targeted Therapies in Breast Cancer Care
Anders, C. K., LeBoeuf, N. R., Bashoura, L., Faiz, S. A., Shariff, A. I., & Thomas, A. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_279465 · Cited by 21
Ji, Y., Abdelhady, A. M., Samant, T. S., Yang, S., & Lorenc, K. R. (2020) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.853 · Cited by 21
Lee, S. H., Im, S., Kim, G. M., Jung, K. H., Kang, S. Y., Park, I. H., Kim, J. H., Lee, K. E., Ahn, H. K., Lee, M. H., et al. (2020) · Cancers · doi:10.3390/cancers12113265 · Cited by 21
“For premenopausal HR+, HER2−MBC patients, CDK4/6 inhibitors plus ET also have demonstrated superior progression-free survival (PFS) versus ET alone in pivotal trials such as MONALEESA-7 [7] and in subpopulations of PALOMA-3 [8] and MONARCH-2 [9].”
MethodSelf-citationCottu, P. H., Ring, A. E., Abdel‐Razeq, H., Marchetti, P., Cardoso, F., Bofill, J. S., Martín, M., Menon-Singh, L., Wu, J., & Laurentiis, M. D. (2022) · The Breast · doi:10.1016/j.breast.2022.01.016 · Cited by 22
Garrido-Castro, A. C., Graham, N., Ali, L. R., Herold, C. I., Desrosiers, J., Do, K., Parsons, H. A., Li, T., Goel, S., DiLullo, M. K., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010430 · Cited by 21
Dauccia, C., Agostinetto, E., Arecco, L., Lobo-Martins, S., Gitto, M., Lyon, A. R., López‐Fernández, T., Dent, S. F., Casalino, G., Agarwala, V., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105128 · Cited by 21
Huang, X., Lin, S., Rao, X., Zeng, D., Wang, H., Weng, X., & Huang, P. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.01.019 · Cited by 21
Lu, Y., Yeo, W., Yap, Y. S., Park, Y. H., Tamura, K., Li, H., & Cheng, R. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00838-x · Cited by 24
Self-citationBolzacchini, E., Pomero, F., Fazio, M., Civitelli, C., Fabro, G., Pellegrino, D., Giordano, M., & Squizzato, A. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.11.009 · Cited by 21
Liquid biopsies to predict CDK4/6 inhibitor efficacy and resistance in breast cancer
Main, S. C., Cescon, D. W., & Bratman, S. V. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.37 · Cited by 24
Sammons, S. L., Raskina, K., Danziger, N. A., Alder, L., Schrock, A. B., Venstrom, J. M., Knutson, K. L., Thompson, E. A., McGregor, K., Sokol, E. S., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00149 · Cited by 23
Queiroz, M. M., Sacardo, K. P., Ribeiro, M. F., Gadotti, L. L., Saddi, R., Oliveira, L. J. D. C., Linck, R. D. M., Cruz, M. R. D. S., Barroso‐Sousa, R., Sahade, M., et al. (2023) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2023.100683 · Cited by 22
Rugo, H. S., Liu, X., Li, B. C., McRoy, L., Chen, C., Layman, R. M., & Brufsky, A. (2023) · International Journal of Cancer · doi:10.1002/ijc.34748 · Cited by 21
Agarwal, N., Castellano, D., Alonso‐Gordoa, T., Arija, J. Á. A., Colomba, É., Gravis, G., Mourey, L., Oudard, S. M., Fléchon, A., González, M., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3436 · Cited by 23
Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer
Yap, Y. S., Chiu, J. W. Y., Ito, Y., Ishikawa, T., Aruga, T., Kim, S. J., Toyama, T., Saeki, T., Saito, M., Gounaris, I., et al. (2020) · Cancer Science · doi:10.1111/cas.14554 · Cited by 20
Self-citationBardia, A., Modi, S., Oliveira, M., Cortés, J., Campone, M., Ma, B., Dirix, L. Y., Weise, A. M., Hewes, B., Diaz-Padilla, I., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1068 · Cited by 21
“The combination of ribociclib [a CDK4/6 inhibitor (CDK4/6i)] with ET is associated with significant improvements in progression-free survival (PFS) (8, 9) and overall survival (10, 11).”
BackgroundSelf-citationGold Derivatives Development as Prospective Anticancer Drugs for Breast Cancer Treatment
Ielo, I., Iacopetta, D., Saturnino, C., Longo, P., Galletta, M., Drommi, D., Rosace, G., Sinicropi, M. S., & Plutino, M. R. (2021) · Applied Sciences · doi:10.3390/app11052089 · Cited by 20
“Abemaciclib and ribociclib showed a relative reduction in the risk of death of 25–30% [9].”
BackgroundCDK Inhibitors and FDA: Approved and Orphan
Cicenas, J., & Simkus, J. (2024) · Cancers · doi:10.3390/cancers16081555 · Cited by 24
“This approval was based on a randomized, double-blind, placebo-controlled, international clinical trial MONALEESA-2 [22], which was confirmed by MONALEESA-3 [23–25] and MONALEESA-7 [26,27] phase III trials. by MONALEESA-3 [23–25] and MONALEESA-7 [26,27] phase III trials.”
MethodMajor clinical research advances in gynecologic cancer in 2019
Kim, M., Suh, D. H., Lee, K.-H., Eom, K., Lee, J., Lee, Y.-Y., Hansen, H. F., Mirza, M. R., & Kim, J. (2020) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2020.31.e48 · Cited by 19
“The updated OS, which was the key secondary endpoint, was reported this year [52].”
BackgroundSelf-citationNew Approaches with Precision Medicine in Adult Brain Tumors
Leibetseder, A., Preusser, M., & Berghoff, A. S. (2022) · Cancers · doi:10.3390/cancers14030712 · Cited by 21
Watson, N. W., Shatzel, J. J., & Al-Samkari, H. T. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2022.12.001 · Cited by 22
Prognostic and immunological characteristics of CDK1 in lung adenocarcinoma: A systematic analysis
Du, Q., Liu, W., Mei, T., Wang, J., Qin, T., & Huang, D. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1128443 · Cited by 22
“The use of CDK4/6 inhibitors optimized the treatment of hormone receptor-positive breast cancer (21, 22).”
MethodFasching, P. A., Decker, T. W., Hartkopf, A. D., Nusch, A., Heinrich, B., Kurbacher, C. M., Fuchs, R., Tesch, H., Krabisch, P., Huober, J., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113480 · Cited by 19
Wang, L., Gao, S., Li, D., Ran, X., Sheng, Z., Wu, W., & Yang, X. (2019) · The Breast Journal · doi:10.1111/tbj.13703 · Cited by 20
Abemaciclib, a CDK4 and CDK6 Inhibitor for the Treatment of Metastatic Breast Cancer
Martín, M., García-Sáenz, J. Á., Manso, L., Llombart‐Cussac, A., Cassinello, A., Atienza, M., Ringeisen, F. P., & Ciruelos, E. (2020) · Future Oncology · doi:10.2217/fon-2020-0604 · Cited by 20
Li, Y., Li, L., Du, Q., Li, Y., Yang, H., & Li, Q. (2021) · Cancer Investigation · doi:10.1080/07357907.2021.1910705 · Cited by 19
Changes in Overall Survival over Time for Patients with de novo Metastatic Breast Cancer
Iwase, T., Shrimanker, T. V., Rodríguez‐Bautista, R., Sahin, O., James, A., Wu, J., Shen, Y., & Ueno, N. T. (2021) · Cancers · doi:10.3390/cancers13112650 · Cited by 21
“71, respectively, in the MONALEESA-2 and MONALEESA-7 trials [12,13].”
BackgroundCurrent State of Cell Therapies for Breast Cancer
Gautam, N., Elleson, K. M., Ramamoorthi, G., & Czerniecki, B. J. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000607 · Cited by 21
Giachetti, P. P. M. B., Morganti, S., Gandini, S., Giudici, F., Marra, A., Nicolò, E., Zattarin, E., Corti, C., Boldrini, L., Verrazzo, A., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.61067 · Cited by 22
Emerging therapies to overcome antiandrogen resistance and beyond in lethal prostate cancer
Huang, F., Li, K., Shevach, J. W., & Wang, Q. (2025) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2025.04.004 · Cited by 29
“243 CDK4/6 inhibitors —previously used in hormone receptor-positive/HER2-negative (HER2-) advanced breast cancer 244 are now evaluated in multiple Phase II/III trials for RB1-expressing mCRPC, either alone or in combination with AR inhibitors.”
Kettner, N. M., Bui, T. N., Navarro-Yepes, J., Ghotbaldini, S., Quintela, B., Luo, C. K., Lam, N., Rao, X., Raghavendra, A. S., Wang, Y., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01041-1 · Cited by 27
“Extended follow-up data have shown an overall survival bene fi t with ribociclib and abemaciclib, whereas results for palbociclib have been less consistent 10 – 14 .”
Self-citationWhole-genome landscapes of 1,364 breast cancers
Kim, R., Yu, J., Lim, J., Oh, B., Nam, S. J., Kim, S. W., Lee, J. E., Chae, B. J., Kim, J., Park, G. E., et al. (2025) · Nature · doi:10.1038/s41586-025-09812-3 · Cited by 27
Wortelboer, N., van Ommen‐Nijhof, A., Konings, I. R. H. M., van der Noort, V., van den Pol, E., Páez, C. G., Bakker, S. D., Hovenga, S., Imholz, A. L. T., Kamm, Y. J. L., et al. (2026) · JAMA Oncology · doi:10.1001/jamaoncol.2025.6585 · Cited by 22
Welslau, M., Hartkopf, A. D., Müller, V., Wöckel, A., Lux, M. P., Janni, W., Ettl, J., Lüftner, D., Belleville, E., Schütz, F., et al. (2019) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1001-9952 · Cited by 18
“The initial data on overall survival following 35 months of follow-up observation in the Monaleesa7 study were recently published in full [3].”
Contemporary breast cancer treatment-associated thrombosis
Kirwan, C., & Blower, E. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2021.12.025 · Cited by 18
Dai, Q., Wang, Y., Liao, M., & Chen, H. (2022) · Annals of Palliative Medicine · doi:10.21037/apm-22-1306 · Cited by 20
Efficacy of CDK 4/6 Inhibitors and Radiotherapy in Breast Cancer Patients with Brain Metastases
Kubeczko, M., Jarząb, M., Krzywon, A., Gräupner, D., Polakiewicz-Gilowska, A., & Gabryś, D. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12052044 · Cited by 18
Lee, E. Y., Lee, D., Lee, K.-H., & Im, S. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2023.846 · Cited by 19
“…–8 ) [13,14], and MONALEE-SA-7 was the first study to demonstrate overall survival (OS) benefits for adding ribociclib to therapy with goserelin and either letrozole or tamoxifen (58.7 vs. 48.0 months; hazard ratio, 0.76; 95% confidence interval [CI], 0.61 to 0.96) [15,16] in premenopausal women.”
BackgroundInfluentialSelf-citationCDK4/6 inhibitors: The Devil is in the Detail
Magge, T., Rajendran, S., Brufsky, A., & Foldi, J. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01540-7 · Cited by 20
Kessler, L. E., Wiklander, O. P. B., Hamberg, E., Bergh, J. C. S., Foukakis, T., & Matikas, A. (2020) · Acta Oncologica · doi:10.1080/0284186x.2020.1804613 · Cited by 20
Prawira, A., Le, T. B. U., Vu, T. C., & Huynh, H. T. (2020) · Liver International · doi:10.1111/liv.14728 · Cited by 19
Løkkegaard, S., Eliáš, D., Alves, C. L., Bennetzen, M. V., Lænkholm, A., Bak, M., Gjerstorff, M. F., Johansen, L. E., Vever, H., Bjerre, C. A., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-020-00210-8 · Cited by 20
Le, V. P., Zhong, L., Narsipur, N., Hays, E. A., Tran, D. K., Rosario, K., & Wilson, L. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.27.3.327 · Cited by 20
Recent updates in systemic therapy of breast cancer: A brief narrative review
Arora, S., & Gogia, A. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_335_20 · Cited by 19
Oligometastatic Breast Cancer: How to Manage It?
Barberi, V., Pietragalla, A., Franceschini, G., Marazzi, F., Paris, I., Cognetti, F., Masetti, R., Scambia, G., & Fabi, A. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060532 · Cited by 18
Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer
Ham, A., Kim, M. H., Kim, G. M., Kim, J. H., Kim, J. Y., Park, H. S., Park, S., Cho, Y. U., Park, B., Kim, S. I., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05750-y · Cited by 17
Self-citationProblematic crossovers in cancer drug trials
Gyawali, B. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00805-7 · Cited by 17
Ji, Y., Schiller, H., Yang, S., Quinlan, M., Darstein, C., Huth, F., Winter, S., & Chakraborty, A. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01338-z · Cited by 18
Yoon, S. M., & Bazan, J. G. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01529-2 · Cited by 19
“…BR-002 likely incorporated molecular targeted agents (such as CDK4/6 inhibitors), HER2-directed monoclonal antibodies, and immunotherapy all of which have shown to substantially delay disease progression over standard endocrine therapy or chemotherapy alone for metastatic breast cancer [110–115].”
BackgroundNovel targeted therapies for metastatic breast cancer
Jazieh, K., Bell, R., Agarwal, N., & Abraham, J. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.03.43 · Cited by 20
Everolimus in Advanced Breast Cancer: A Systematic Review and Meta-analysis
Raphael, J., Lefebvre, C., Allan, A. L., Helou, J. A., Boldt, G., Vandenberg, T. A., & Blanchette, P. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00770-6 · Cited by 18
Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
Yang, J., Han, J., Tian, M., Tian, K., Liao, W., & Yan, X. (2020) · Cancer Management and Research · doi:10.2147/cmar.s284556 · Cited by 18
Jeong, E., Wang, C., Wilson, L., & Zhong, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.658054 · Cited by 17
“The types and probabilities of AEs were derived from the results of the MONALEESA-7 clinical trial and were modeled as a one-time event (20).”
BackgroundMethodInfluentialMouabbi, J. A., Osborne, C. K., Schiff, R., & Rimawi, M. F. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06383-5 · Cited by 21
“The PARSIFAL trial showed that palbociclib with letrozole yielded similar outcomes to those of palbociclib with mPFS median progression-free survival duration, HR hazard ratio, mOS median overall survival duration, AI aromatase inhibitor, 1L first-line, 2L second-line MONALEESA-2 [31] Ribociclib or placebo + letrozole…”
BackgroundInfluentialHuo, X., Shen, G., Li, J., Wang, M., Xie, Q., Zhao, F., Ren, D., Dong, Q., & Zhao, J. (2021) · Gene · doi:10.1016/j.gene.2021.146094 · Cited by 17
Campone, M., Laurentiis, M. D., Zamagni, C., Kudryavcev, I., Agterof, M. J., Brown-Glaberman, U. A., Palácová, M., Chatterjee, S., Menon-Singh, L., Wu, J., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06543-1 · Cited by 19
“Ribociclib is an oral, selective, cyclin-dependent kinases 4 and 6 inhibitor (CDK4/6i) approved for use in combination with ET for the treatment of females with HR+, human epidermal growth factor receptor 2-negative (HER2−) ABC [15, 16].”
BackgroundResultInfluentialVisani, L., Livi, L., Ratoša, I., Oražem, M., Ribnikar, D., Saieva, C., Becherini, C., Salvestrini, V., Scoccimarro, E., Valzano, M., et al. (2022) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2022.10.023 · Cited by 17
He, F., Zhang, Q., Chen, Y., Ge, S., Xie, Y., Sun, R., Wu, Y., & Xu, J. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5564 · Cited by 24
Lüftner, D., Schneeweiß, A., Hartkopf, A. D., Müller, V., Wöckel, A., Janni, W., Ettl, J., Belleville, E., Schütz, F., Thill, M., et al. (2020) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1111-8775 · Cited by 18
Sharaf, B., Abu‐Fares, H., Tamimi, F., Al-Sawajneh, S. F., Salama, O., Daoud, R., Alhajahjeh, A. A., Al-lababidi, S., & Abdel‐Razeq, H. (2023) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s415432 · Cited by 18
Chen, B.-F., Tsai, Y., Chao, T., Lien, P., Lin, Y., Feng, C.-J., Chen, Y.-J., Cheng, H.-F., Liu, C., Lai, J., et al. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01458-1 · Cited by 17
“The MONALEESA-7 trial enrolled approximately 27.7% of premenopausal and around 30% of Asian patients, which may have influenced physicians’ choices [19].”
InfluentialRibociclib-Induced Pneumonitis: A Case Report
Algwaiz, G., Badran, A. A., Elshenawy, M. A., & Al‐Tweigeri, T. (2020) · Breast Care · doi:10.1159/000507647 · Cited by 16
Servetto, A., Napolitano, F., Angelis, C. D., Placido, P. D., Giuliano, M., Arpino, G., Placido, S. D., Bianco, R., & Formisano, L. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103191 · Cited by 18
“Abemaciclib, palbociclib and ribocliclib have been tested, in combination with hormone therapy, in phase III randomized clinical trials, demonstrating a clinically significant benefit [1-12] and improved survival”
BackgroundAmaro, C. P., Batra, A., & Lupichuk, S. (2021) · Current Oncology · doi:10.3390/curroncol28030209 · Cited by 16
“, time to third-line treatment) are reported by the pivotal RCTs that continue to demonstrate the superiority of the CDK4/6i + AI arm [28,31,32].”
BackgroundCombined endocrine and targeted therapy in luminal breast cancer
Cesca, M. G., Pandolfi, N. C., Maciel, D., Lima, J., Sanches, S. M., & Ponde, N. F. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1960160 · Cited by 19
“exclusively pre-menopausal sample, showed similar results [64,65].”
BackgroundMiglietta, F., Cinquini, M., Dieci, M. V., Cortesi, L., Criscitiello, C., Montemurro, F., Mastro, L. D., Zambelli, A., Biganzoli, L., Levaggi, A., et al. (2022) · The Breast · doi:10.1016/j.breast.2022.10.014 · Cited by 20
Han, Y., Wang, J., Wang, Z., & Xu, B. (2020) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2020.100606 · Cited by 17
Agapow, P., Mulla, R., Markuzon, N., Ottesen, L. H., & Meulendijks, D. (2023) · Future Oncology · doi:10.2217/fon-2022-0616 · Cited by 18
André, F., Solovieff, N., Su, F., Bardia, A., Neven, P., Yap, Y. S., Tripathy, D., Lu, Y., Slamon, D., Chia, S., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.09.010 · Cited by 18
Self-citationMai, N., dos Anjos, C. H., Razavi, P., Safonov, A. M., Patil, S., Chen, Y., Drago, J. Z., Modi, S., Bromberg, J., Dang, C. T., et al. (2024) · npj Breast Cancer · doi:10.1038/s41523-024-00699-3 · Cited by 16
Fasching, P. A., Slamon, D. J., Nowecki, Z. I., Kukiełka-Budny, B., Stroyakovskiy, D., Yardley, D. A., Huang, C., Chan, A., Chia, S., Martín, M., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1724 · Cited by 16
Self-citationHartkopf, A. D., Müller, V., Wöckel, A., Lux, M. P., Janni, W., Ettl, J., Belleville, E., Schütz, F., Fasching, P. A., Kolberg, H., et al. (2019) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1039-4458 · Cited by 17
Garufi, G., Carbognin, L., Orlandi, A., Palazzo, A., Tortora, G., & Bria, E. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.651723 · Cited by 15
“001) (38), then confirmed by the efficacy in median OS (20).”
BackgroundMethodWong, V., BOER, R. D., Baron-Hay, S. E., Blum, R., Boyle, F. M., Chua, S. L. L., Clarke, K., Cuff, K. E., Green, M., Lim, E., et al. (2022) · Clinical Breast Cancer · doi:10.1016/j.clbc.2022.08.011 · Cited by 19
Alpelisib in the Treatment of Metastatic HR+ Breast Cancer with PIK3CA Mutations
Mavratzas, A., & Marmé, F. (2020) · Future Oncology · doi:10.2217/fon-2020-0464 · Cited by 16
Ribociclib plus fulvestrant in the treatment of breast cancer
Neven, P., Sonke, G. S., & Jérusalem, G. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1840360 · Cited by 16
Trends and patterns in the use of opioids among metastatic breast cancer patients
Shen, C., Thornton, J. D., Newport, K. B., Schaefer, É., Zhou, S., Yee, N. S., Dodge, D. G., & LESLIE, D. L. (2020) · Scientific Reports · doi:10.1038/s41598-020-78569-8 · Cited by 16
Network controllability solutions for computational drug repurposing using genetic algorithms
Popescu, V., Kanhaiya, K., Năstac, I., Czeizler, E., & Petre, I. (2022) · Scientific Reports · doi:10.1038/s41598-022-05335-3 · Cited by 18
Hart, L. L., Im, S., Tolaney, S. M., Campone, M., Pluard, T., Sousa, B., Freyer, G., Decker, T., Kalinsky, K. M., Sopher, G. M., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115225 · Cited by 17
Self-citationHER2 expression in breast cancer: evidence gaps and challenges
Atallah, N. M., Quinn, C., & Rakha, E. A. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01209-9 · Cited by 20
“The cyclin D1-CDK4/6 pathway has been shown to mediate treatment resistanceinHER2-positiveBC 155 – 158 .”
Verret, B., Sourisseau, T., Stefanovska, B., Mosele, F., Tran-Dien, A., & André, F. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3260 · Cited by 15
Wu, J., Luo, M., Chen, Z., Li, L., & Huang, X. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.737656 · Cited by 16
“Until today, BRCA is the most frequent malignancy in the world (Karami and Mehdipour, 2013; Balic et al., 2019; Harbeck et al., 2019).”
BackgroundJi, Y., Darstein, C., Yang, S., Quinlan, M., Chakravartty, A., Zarate, J. P., Chakraborty, A., & Ho, Y. (2023) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2310 · Cited by 14
Self-citationKhorrami, M., Viswanathan, V. S., Reddy, P., Braman, N. M., Kunte, S., Gupta, A. B., Abraham, J., Montero, A. J., & Madabhushi, A. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00574-7 · Cited by 15
Advanced Breast Cancer Care: The Current Situation and Global Disparities
Ghose, A., Stanway, S. J., Sirohi, B., Mutebi, M. C., & Adomah, S. (2023) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2023.151551 · Cited by 15
Jhaveri, K. L., O’Shaughnessy, J., Fasching, P. A., Tolaney, S. M., Yardley, D. A., Sharma, V. K., Biswas, C., Thuerigen, A., Pathak, P., & Rugo, H. S. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231216095 · Cited by 16
Pilehvari, A., Kimmick, G. G., You, W., Bonilla, G., & Anderson, R. T. (2024) · Breast Cancer Research · doi:10.1186/s13058-024-01902-w · Cited by 16
Antoine, A., Pérol, D., Robain, M., Bachelot, T., Choquet, R., Jacot, W., Yahia, B. B. H., Grinda, T., Delaloge, S., Lasset, C., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115072 · Cited by 15
Ahn, H. K., Kim, J., Lee, K.-H., Kim, G. M., Kang, S. Y., Lee, K. S., Kim, J. H., Lee, K. E., Lee, M. H., Kim, H. J., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00006-3 · Cited by 17
Self-citationmiR-1298-5p Influences the Malignancy Phenotypes of Breast Cancer Cells by Inhibiting CXCL11
Zhang, J., & Da-wei, H. (2021) · Cancer Management and Research · doi:10.2147/cmar.s279121 · Cited by 16
Pharmacokinetics of Ribociclib in Subjects With Hepatic Impairment
Samant, T. S., Yang, S., Miller, M. C., & Ji, Y. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1825 · Cited by 14
Metadata
- Authors
- Im, S.-A., Lu, Y.-S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., Chow, L., Sohn, J., Lee, K.-S., Campos-Gomez, S., Villanueva-Vazquez, R., Jung, K.-H., Chakravartty, A., Hughes, G., Gounaris, I., Rodriguez-Lorenc, K., Taran, T., Hurvitz, S., & Tripathy, D.
- Affiliations
- Seoul National University (KR)
- Harvard University (US)
- From Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), the Yonsei Cancer Center, Yonsei University Health System (J.S.), and the Asan Medical Center, University of Ulsan College of Medicine (K.-H.J.), Seoul, and the Center for Breast Cancer, National Cancer Center, Gyeonggi-do (K.-S.L.) — all in South Korea; National Taiwan University Hospital, Taipei, Taiwan (Y.-S.L.); Massachusetts General Hospital Cancer Center and Harvard...
- Novartis (Switzerland) (CH)
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-07-25
- Volume
- 381
- Issue
- 4
- Pages
- 307-316
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2948069739
- Cited by
- 1,001
- References
- 32
- Citations by year
- 2026: 68 · 2025: 119 · 2024: 121 · 2023: 152 · 2022: 159 · 2021: 165 · 2020: 174 · 2019: 42
- FWCI
- 100.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Novartis
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- ribociclib, CDK4/6 inhibitors, endocrine therapy, hormone receptor-positive breast cancer, HER2-negative breast cancer, overall survival, aromatase inhibitors, goserelin, tamoxifen, progression-free survival, disease progression, second-line therapy, antineoplastic therapy, treatment-related adverse events, neutropenia
- MeSH terms
- Adult, Aminopyridines, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Female, Follow-Up Studies, Humans, Middle Aged, Purines, Receptors, Estrogen, Receptors, Progesterone, Tamoxifen, Survival Analysis, Premenopause, Erb-b2 Receptor Tyrosine Kinases, Cyclin-Dependent Kinases, Aromatase Inhibitors, Protein Kinase Inhibitors, Perimenopause, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.